NERM
EBS icon

New England Research & Management’s Emergent Biosolutions EBS Stock Holding History

New England Research & Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,050
Closed -$452K – 175
2020
Q4 		$452K Buy
+5,050
New +$463K 0.28% 105
2020
Q3 		– Sell
-4,500
Closed -$356K – 142
2020
Q2 		$356K Buy
+4,500
New +$335K 0.25% 113

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

New England Research & Management's EBS Position: Q1 2021 in Review

New England Research & Management sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 5,050 shares — an estimated $452K sold.

New England Research & Management first reported a position in EBS in Q2 2020 and held it in 2 quarters. The position peaked at $452K in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • New England Research & Management reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • New England Research & Management sold 5,050 Emergent Biosolutions shares in Q1 2021, an estimated $452K.
  • New England Research & Management first reported a position in Emergent Biosolutions in Q2 2020 and held it in 2 quarters.
  • New England Research & Management's Emergent Biosolutions position peaked at $452K in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on New England Research & Management's 13F filing for Q1 2021, filed 16 Apr 2021.